Aclaris Therapeutics (ACRS) Given a $50.00 Price Target by Cantor Fitzgerald Analysts

Aclaris Therapeutics (NASDAQ:ACRS) received a $50.00 target price from equities research analysts at Cantor Fitzgerald in a report released on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 203.77% from the stock’s current price.

A number of other brokerages have also issued reports on ACRS. BidaskClub raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Zacks Investment Research lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Leerink Swann cut their price objective on shares of Aclaris Therapeutics from $56.00 to $54.00 and set an “outperform” rating for the company in a report on Tuesday, March 13th. Finally, Guggenheim started coverage on shares of Aclaris Therapeutics in a report on Thursday, February 8th. They set a “buy” rating and a $53.00 price objective for the company. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $43.50.

How to Become a New Pot Stock Millionaire

Aclaris Therapeutics stock opened at $16.46 on Friday. Aclaris Therapeutics has a 12-month low of $16.01 and a 12-month high of $33.10.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The firm had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $0.80 million. equities research analysts forecast that Aclaris Therapeutics will post -4.27 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Franklin Resources Inc. grew its holdings in Aclaris Therapeutics by 27.9% during the 4th quarter. Franklin Resources Inc. now owns 2,596,814 shares of the biotechnology company’s stock valued at $64,037,000 after buying an additional 565,945 shares in the last quarter. BlackRock Inc. grew its holdings in Aclaris Therapeutics by 28.4% during the 4th quarter. BlackRock Inc. now owns 2,195,028 shares of the biotechnology company’s stock valued at $54,129,000 after buying an additional 485,146 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in Aclaris Therapeutics by 3.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 892,298 shares of the biotechnology company’s stock valued at $23,030,000 after buying an additional 29,896 shares in the last quarter. Driehaus Capital Management LLC grew its holdings in Aclaris Therapeutics by 73.8% during the 4th quarter. Driehaus Capital Management LLC now owns 523,428 shares of the biotechnology company’s stock valued at $12,908,000 after buying an additional 222,254 shares in the last quarter. Finally, Alyeska Investment Group L.P. grew its holdings in Aclaris Therapeutics by 85.2% during the 3rd quarter. Alyeska Investment Group L.P. now owns 467,884 shares of the biotechnology company’s stock valued at $12,076,000 after buying an additional 215,201 shares in the last quarter. 92.19% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3341065/aclaris-therapeutics-acrs-given-a-50-00-price-target-by-cantor-fitzgerald-analysts.html.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

GeoCoin  One Day Trading Volume Hits $58,125.00
GeoCoin One Day Trading Volume Hits $58,125.00
Equal Reaches 1-Day Trading Volume of $12,722.00
Equal Reaches 1-Day Trading Volume of $12,722.00
Financial Review: Rush Enterprises  & Its Rivals
Financial Review: Rush Enterprises & Its Rivals
$709.63 Million in Sales Expected for STERIS  This Quarter
$709.63 Million in Sales Expected for STERIS This Quarter
$919.88 Million in Sales Expected for Old Dominion Freight Line  This Quarter
$919.88 Million in Sales Expected for Old Dominion Freight Line This Quarter
Meridian Bancorp  Receives Consensus Recommendation of “Buy” from Analysts
Meridian Bancorp Receives Consensus Recommendation of “Buy” from Analysts


Leave a Reply

© 2006-2018 Ticker Report. Google+.